Bicalutamide 150 mg in addition to standard care for patients with early non-metastatic prostate cancer: updated results from the Scandinavian Prostate Cancer Period Group-6 Study after a median follow-up period of 7.1 years

Peter Iversen; Jan-Erik Johansson; Pär Lodding; Timo Kylmälä; Per Lundmo; Peter Klarskov; Teuvo L J Tammela; Ilker Tasdemir; Thomas Morris; Jon Armstrong; Scandinavian Prostate Cancer Group

doi:10.1080/00365590601017329

Bicalutamide 150 mg in addition to standard care for patients with early non-metastatic prostate cancer: updated results from the Scandinavian Prostate Cancer Period Group-6 Study after a median follow-up period of 7.1 years

Peter Iversen, Jan-Erik Johansson, Pär Lodding, Timo Kylmälä, Per Lundmo, Peter Klarskov, Teuvo L J Tammela, Ilker Tasdemir, Thomas Morris, Jon Armstrong, Scandinavian Prostate Cancer Group

36 Citationer (Scopus)

Abstract

The Early Prostate Cancer (EPC) programme is evaluating the efficacy and tolerability of bicalutamide following standard care (radiotherapy, radical prostatectomy or watchful waiting) in patients with localized (T1-2, N0/Nx) or locally advanced (T3-4, any N; or any T, N + ) non-metastatic prostate cancer. Herein we report the latest findings after a median follow-up period of 7.1 years from the Scandinavian Prostate Cancer Group (SPCG)-6 study, one of three trials in the EPC programme.

Originalsprog	Engelsk
Tidsskrift	Scandinavian Journal of Urology and Nephrology
Vol/bind	40
Udgave nummer	6
Sider (fra-til)	441-52
Antal sider	12
ISSN	0036-5599
DOI	https://doi.org/10.1080/00365590601017329
Status	Udgivet - 1 jan. 2006

Adgang til dokumentet

10.1080/00365590601017329

Fingeraftryk

Dyk ned i forskningsemnerne om 'Bicalutamide 150 mg in addition to standard care for patients with early non-metastatic prostate cancer: updated results from the Scandinavian Prostate Cancer Period Group-6 Study after a median follow-up period of 7.1 years'. Sammen danner de et unikt fingeraftryk.

Citationsformater

Iversen, P., Johansson, J.-E., Lodding, P., Kylmälä, T., Lundmo, P., Klarskov, P., Tammela, T. L. J., Tasdemir, I., Morris, T., Armstrong, J., & Scandinavian Prostate Cancer Group (2006). Bicalutamide 150 mg in addition to standard care for patients with early non-metastatic prostate cancer: updated results from the Scandinavian Prostate Cancer Period Group-6 Study after a median follow-up period of 7.1 years. Scandinavian Journal of Urology and Nephrology, 40(6), 441-52. https://doi.org/10.1080/00365590601017329

Bicalutamide 150 mg in addition to standard care for patients with early non-metastatic prostate cancer: updated results from the Scandinavian Prostate Cancer Period Group-6 Study after a median follow-up period of 7.1 years. / Iversen, Peter; Johansson, Jan-Erik; Lodding, Pär et al.
I: Scandinavian Journal of Urology and Nephrology, Bind 40, Nr. 6, 01.01.2006, s. 441-52.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning

Iversen, P, Johansson, J-E, Lodding, P, Kylmälä, T, Lundmo, P, Klarskov, P, Tammela, TLJ, Tasdemir, I, Morris, T, Armstrong, J & Scandinavian Prostate Cancer Group 2006, 'Bicalutamide 150 mg in addition to standard care for patients with early non-metastatic prostate cancer: updated results from the Scandinavian Prostate Cancer Period Group-6 Study after a median follow-up period of 7.1 years', Scandinavian Journal of Urology and Nephrology, bind 40, nr. 6, s. 441-52. https://doi.org/10.1080/00365590601017329

Iversen P, Johansson JE, Lodding P, Kylmälä T, Lundmo P, Klarskov P et al. Bicalutamide 150 mg in addition to standard care for patients with early non-metastatic prostate cancer: updated results from the Scandinavian Prostate Cancer Period Group-6 Study after a median follow-up period of 7.1 years. Scandinavian Journal of Urology and Nephrology. 2006 jan. 1;40(6):441-52. doi: 10.1080/00365590601017329

Iversen, Peter ; Johansson, Jan-Erik ; Lodding, Pär et al. / Bicalutamide 150 mg in addition to standard care for patients with early non-metastatic prostate cancer: updated results from the Scandinavian Prostate Cancer Period Group-6 Study after a median follow-up period of 7.1 years. I: Scandinavian Journal of Urology and Nephrology. 2006 ; Bind 40, Nr. 6. s. 441-52.

@article{f7752cc10fef4de9b0072b3a568e449f,

title = "Bicalutamide 150 mg in addition to standard care for patients with early non-metastatic prostate cancer: updated results from the Scandinavian Prostate Cancer Period Group-6 Study after a median follow-up period of 7.1 years",

abstract = "The Early Prostate Cancer (EPC) programme is evaluating the efficacy and tolerability of bicalutamide following standard care (radiotherapy, radical prostatectomy or watchful waiting) in patients with localized (T1-2, N0/Nx) or locally advanced (T3-4, any N; or any T, N + ) non-metastatic prostate cancer. Herein we report the latest findings after a median follow-up period of 7.1 years from the Scandinavian Prostate Cancer Group (SPCG)-6 study, one of three trials in the EPC programme.",

author = "Peter Iversen and Jan-Erik Johansson and P{\"a}r Lodding and Timo Kylm{\"a}l{\"a} and Per Lundmo and Peter Klarskov and Tammela, {Teuvo L J} and Ilker Tasdemir and Thomas Morris and Jon Armstrong and {Scandinavian Prostate Cancer Group}",

year = "2006",

month = jan,

day = "1",

doi = "10.1080/00365590601017329",

language = "English",

volume = "40",

pages = "441--52",

journal = "Scandinavian Journal of Urology and Nephrology",

issn = "0036-5599",

publisher = "Taylor & Francis",

number = "6",

}

TY - JOUR

T1 - Bicalutamide 150 mg in addition to standard care for patients with early non-metastatic prostate cancer: updated results from the Scandinavian Prostate Cancer Period Group-6 Study after a median follow-up period of 7.1 years

AU - Iversen, Peter

AU - Johansson, Jan-Erik

AU - Lodding, Pär

AU - Kylmälä, Timo

AU - Lundmo, Per

AU - Klarskov, Peter

AU - Tammela, Teuvo L J

AU - Tasdemir, Ilker

AU - Morris, Thomas

AU - Armstrong, Jon

AU - Scandinavian Prostate Cancer Group

PY - 2006/1/1

Y1 - 2006/1/1

N2 - The Early Prostate Cancer (EPC) programme is evaluating the efficacy and tolerability of bicalutamide following standard care (radiotherapy, radical prostatectomy or watchful waiting) in patients with localized (T1-2, N0/Nx) or locally advanced (T3-4, any N; or any T, N + ) non-metastatic prostate cancer. Herein we report the latest findings after a median follow-up period of 7.1 years from the Scandinavian Prostate Cancer Group (SPCG)-6 study, one of three trials in the EPC programme.

AB - The Early Prostate Cancer (EPC) programme is evaluating the efficacy and tolerability of bicalutamide following standard care (radiotherapy, radical prostatectomy or watchful waiting) in patients with localized (T1-2, N0/Nx) or locally advanced (T3-4, any N; or any T, N + ) non-metastatic prostate cancer. Herein we report the latest findings after a median follow-up period of 7.1 years from the Scandinavian Prostate Cancer Group (SPCG)-6 study, one of three trials in the EPC programme.

U2 - 10.1080/00365590601017329

DO - 10.1080/00365590601017329

M3 - Journal article

C2 - 17130095

SN - 0036-5599

VL - 40

SP - 441

EP - 452

JO - Scandinavian Journal of Urology and Nephrology

JF - Scandinavian Journal of Urology and Nephrology

IS - 6

ER -